Can I Take Green Tea Extract / EGCG with AOD-9604?

What Is AOD-9604 and Why Do People Stack It with Green Tea Extract?

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal end of human growth hormone (residues 176 to 191). It does not bind the GH receptor the way full-length GH does, so it avoids the insulin-resistance and IGF-1 elevation associated with exogenous GH. Its proposed mechanism centers on stimulating lipolysis and inhibiting lipogenesis through beta-3 adrenergic-like pathways in adipose tissue.

The METAOD001 Phase II trial enrolled 300 obese adults across multiple Australian centers and tested AOD-9604 doses from 1 mg to 54 mg per day orally. The 1 mg oral dose produced statistically meaningful reductions in body fat mass over 12 weeks compared to placebo, while higher doses did not proportionally outperform it. [1] That inverted dose-response curve is one reason compounding pharmacies now favor subcutaneous injection of 250 to 500 mcg daily, which delivers more predictable plasma exposure than oral dosing.

Green tea extract is layered on top by patients and some practitioners because epigallocatechin-3-gallate (EGCG), the primary catechin in the extract, activates AMPK, suppresses fatty acid synthase, and modestly inhibits catechol-O-methyltransferase (COMT), leading to prolonged norepinephrine activity in adipose tissue. [2] The theoretical appeal is additive fat-oxidation signaling through complementary pathways. The practical concern is that EGCG carries its own safety profile that can interact with the clinical picture created by AOD-9604 use.

AOD-9604 Regulatory and Compounding Status

AOD-9604 is not approved by the FDA for any indication. It was removed from the FDA's list of bulk substances permitted for use in 503A compounding in 2015 and again flagged in subsequent guidance, though it remains available through some 503A compounding pharmacies operating under physician prescription in the United States. Prescribers using it do so off-label for adipose modulation in a research context. [3]

Patients receiving AOD-9604 through a telehealth provider are therefore already accepting some regulatory ambiguity. Adding a supplement with its own dose-dependent toxicity profile means the safety margin of the overall regimen narrows, and monitoring becomes proportionally more important.

How AOD-9604 Is Cleared

AOD-9604 has a subcutaneous half-life of approximately 30 minutes based on pharmacokinetic modeling from the METAOD program. [1] It is primarily cleared by peptidase activity in plasma and peripheral tissue. Because it is a small peptide and not a prodrug metabolized by hepatic cytochrome P450 enzymes, CYP-mediated drug-drug interactions with AOD-9604 itself are not the primary concern. The concern is unidirectional: EGCG's effects on CYP enzymes and on hepatic oxidative stress may alter the metabolic environment in ways that matter when any compound is co-administered.

What Is EGCG and What Are Its Known Risks?

EGCG is the most pharmacologically active catechin in Camellia sinensis. A standard brewed cup of green tea delivers 50 to 100 mg of EGCG. Concentrated supplements commonly sold in the United States range from 200 mg to 1,000 mg per capsule, with some products providing 2 to 3 g of total catechins daily. [4]

Hepatotoxicity: The Dose-Dependent Signal

The European Food Safety Authority (EFSA) completed a full safety assessment of green tea catechins in 2018 and concluded that EGCG intakes above 800 mg per day from supplements are associated with signs of liver stress in a minority of users, and that 400 mg per day represents the tolerable upper level for most adults. [5] This is not a theoretical concern. The National Institutes of Health LiverTox database lists green tea extract as a "likely" cause of clinically apparent liver injury, with at least 50 well-documented case reports in the literature. [6]

A 2020 systematic review and meta-analysis by Hu and colleagues examined 15 randomized controlled trials (N = 1,243) and found that green tea extract supplementation raised ALT by a mean of 4.1 IU/L (95% CI: 1.8 to 6.4 IU/L) compared with placebo, a statistically significant signal even at doses many practitioners consider moderate. [7] The mechanism appears to involve EGCG-driven production of reactive oxygen species (ROS) in hepatocytes under pro-oxidant conditions, which is the opposite of the antioxidant effect EGCG produces at lower concentrations.

CYP Enzyme Inhibition by EGCG

Several in vitro and clinical pharmacokinetic studies show that EGCG inhibits CYP3A4 and CYP2B6 at concentrations achievable with high-dose supplementation. A 2019 study by Misaka and colleagues demonstrated that a single 800 mg EGCG dose reduced midazolam (a CYP3A4 probe) AUC by approximately 26% in healthy volunteers, suggesting mixed induction and inhibition depending on dose and timing. [8] At doses below 400 mg, this effect is clinically negligible for most drugs. AOD-9604, because it is peptidase-cleared rather than CYP-cleared, is not directly affected. The relevance for patients is indirect: if they are also taking other CYP3A4-metabolized compounds (statins, hormonal contraceptives, certain anxiolytics), adding high-dose EGCG changes their pharmacokinetic environment.

COMT Inhibition and Adrenergic Effects

EGCG inhibits COMT, the enzyme that degrades catecholamines including epinephrine and norepinephrine. [2] AOD-9604 is proposed to act partly through beta-3 adrenergic stimulation in adipose tissue. If EGCG prolongs catecholamine half-life while AOD-9604 concurrently stimulates beta-3 receptors, the combined adrenergic tone could theoretically raise heart rate and blood pressure in susceptible individuals. This is a pharmacodynamic interaction, not a pharmacokinetic one, and the magnitude in humans at typical supplement doses is modest. One randomized crossover study (N = 14) found that 270 mg of EGCG raised resting metabolic rate by 4.6% without significantly altering heart rate. [9] Still, patients with pre-existing hypertension or cardiac arrhythmia should use both compounds cautiously.

Pharmacokinetic Interaction Mechanics: What Actually Overlaps?

The short half-life of AOD-9604 (roughly 30 minutes post-injection) means it is largely cleared before EGCG reaches peak plasma concentration, provided an adequate separation window is maintained.

Timing the Doses

EGCG peaks in plasma at approximately 1.5 to 2 hours after oral ingestion. [4] AOD-9604 is typically injected subcutaneously in the morning, fasting, to maximize lipolytic signaling. If the patient injects AOD-9604 first and waits 2 hours before taking their green tea extract supplement, plasma AOD-9604 has largely been degraded by the time EGCG reaches peak levels. This removes the theoretical window during which EGCG's pro-oxidant hepatic load and any adrenergic amplification could coincide with active peptide exposure.

The 2-hour separation recommendation is grounded in the pharmacokinetics of both compounds rather than a head-to-head interaction study (none exists). This is a gap in the literature that a prospective PK study should address.

Fasted vs. Fed State

EGCG bioavailability drops by roughly 60% when taken with food. [10] AOD-9604 is commonly injected fasted. Patients who inject fasted and then take EGCG with breakfast are already creating a natural time gap and a lower-peak-EGCG scenario. Patients who take EGCG fasted alongside the injection lose both the bioavailability dampening of food and the time separation, which is the higher-risk pattern.

Summary of Interaction Classification

| Interaction Type | Mechanism | Clinical Magnitude at Recommended Doses | |---|---|---| | Pharmacokinetic (direct) | None documented; AOD-9604 is peptidase-cleared | Negligible | | Pharmacokinetic (indirect CYP) | EGCG inhibits CYP3A4 and CYP2B6 at high doses | Low at EGCG <400 mg/day | | Pharmacodynamic (hepatic) | EGCG ROS generation; additive liver stress | Low-moderate; dose-dependent | | Pharmacodynamic (adrenergic) | EGCG COMT inhibition potentiates catecholamines | Low at standard doses |

Hepatotoxicity Risk Assessment When Combining Both Compounds

AOD-9604 at the doses used in compounding practice (250 to 500 mcg/day subcutaneously) has not been independently associated with hepatotoxicity in the published METAOD trial data or in post-marketing surveillance literature. [1] The liver risk in this combination sits almost entirely with EGCG.

Patient Risk Stratification

Three patient groups warrant closer attention before starting this combination.

Patients with pre-existing liver disease, including non-alcoholic fatty liver disease (NAFLD), face a higher baseline risk from EGCG because hepatocytes in a steatotic or inflamed liver are more sensitive to oxidative stress. NAFLD prevalence in adults seeking weight-loss peptide therapy is substantial, possibly 25 to 30% given the metabolic profile of this population. [11]

Patients taking other potentially hepatotoxic compounds simultaneously, such as acetaminophen at regular doses, statins, or certain antifungals, stack their liver burden on top of EGCG's contribution.

Patients taking high-dose EGCG products marketed as fat burners that combine EGCG with synephrine, caffeine, or other thermogenics may not realize how much total EGCG they are ingesting per day. Doses above 800 mg EGCG daily are not uncommon in these products.

Laboratory Monitoring Protocol

The EFSA 2018 guidance recommends monitoring liver function tests before starting concentrated green tea extract supplementation. [5] For patients combining EGCG with AOD-9604 on a HealthRX protocol, the recommended monitoring schedule is:

• Baseline ALT, AST, ALP, and total bilirubin before starting either compound
• Repeat at 8 weeks
• Repeat at 12 weeks, then every 12 weeks if values remain within reference range

Discontinue EGCG if ALT rises above 3 times the upper limit of normal (ULN) or if the patient develops right upper quadrant discomfort, jaundice, or unexplained fatigue. The FDA Drug-Induced Liver Injury Network (DILIN) defines clinically significant liver injury as ALT >3x ULN with bilirubin >2x ULN, a threshold sometimes called Hy's Law. [12]

What the Guidelines and Expert Sources Say

The Natural Medicines Comprehensive Database rates the interaction between green tea and "growth hormone-related peptides" as having insufficient evidence to characterize, reflecting the absence of head-to-head pharmacokinetic data. [13] This is clinically important: absence of evidence for an interaction does not mean the interaction does not exist.

The EFSA's 2018 opinion stated directly: "The Panel concludes that catechin intakes from green tea extracts that have been associated with adverse liver effects are from supplements providing 800 mg or more of EGCG per day." [5] This is the clearest dose threshold in the primary guidance literature.

The American College of Gastroenterology's Clinical Practice Guidelines on drug-induced liver disease note that herbal and dietary supplements now account for approximately 20% of hepatotoxicity cases reported to DILIN, with green tea extract being one of the most frequently implicated single-ingredient products. [14]

"Supplement-induced liver injury is increasingly recognized as a major clinical problem, and green tea extract is among the top herbal causes seen in our registry," wrote Chalasani and colleagues in their 2021 review of DILIN data published in Hepatology. [14]

Practical Clinical Guidance for Patients Already Taking Both

Some patients start green tea extract before beginning AOD-9604, or add it after. Here is the step-by-step approach regardless of which came first.

Step 1: Audit Total Daily EGCG

Add up every source: standalone EGCG capsules, pre-workout formulas, fat burner stacks, and any green tea beverage consumed in large volumes. Stay below 400 mg EGCG per day total. Most brewed green tea contributes 50 to 100 mg per cup, so two to four cups of tea daily is generally below the threshold even before any supplement is added. Supplement labels often list "green tea extract standardized to X% EGCG," so multiply the extract dose by the EGCG percentage to calculate actual EGCG milligrams.

Step 2: Structure the Dose Separation

Inject AOD-9604 subcutaneously in the fasted morning state. Wait a minimum of 2 hours before taking any EGCG-containing supplement. Taking EGCG with a meal (not fasted) further blunts peak plasma EGCG by approximately 60%, reducing the hepatic oxidative load. [10]

Step 3: Get Baseline Labs Before Continuing

If labs have not been drawn in the previous 90 days, order a comprehensive metabolic panel (CMP) including ALT, AST, ALP, and total bilirubin before the next dose. Do not wait for symptoms.

Step 4: Watch for Early Warning Symptoms

Prodromal symptoms of EGCG hepatotoxicity include fatigue, nausea, right upper quadrant discomfort, and dark urine. These may precede lab abnormalities by days. Patients should report any of these symptoms to their prescriber promptly rather than waiting for a scheduled check-in.

Step 5: Reassess the Rationale

Green tea extract at low doses (200 to 400 mg EGCG) produces modest fat-oxidation benefits. A 2007 meta-analysis by Hursel and colleagues (14 studies, N = 1,044) found that green tea catechins combined with caffeine produced an additional 1.2 kg weight loss over 12 weeks compared to caffeine alone. [15] This is a measurable but modest effect. Patients and prescribers should weigh this expected benefit against the monitoring burden and the theoretical additive risk in the context of an already-experimental peptide regimen.

Special Populations and Scenarios

Patients Using AOD-9604 Alongside TRT or HRT

Testosterone and some estrogens are metabolized by CYP3A4. If EGCG at doses above 400 mg/day modestly inhibits CYP3A4, free testosterone or estradiol levels could shift. This would be a small effect at typical EGCG supplement doses, but patients already dialing in hormone levels should be aware that adding high-dose EGCG is another variable. Labs drawn during EGCG use may not fully reflect the steady-state hormone levels present without it.

Patients with Known COMT Gene Variants

COMT Val158Met polymorphism (rs4680) affects how efficiently an individual metabolizes catecholamines. Patients who are homozygous for the low-activity Met/Met variant already have slower catecholamine degradation. Adding EGCG's COMT-inhibiting effect on top of this genetic background could amplify adrenergic tone more than in the general population. Genetic testing panels that include rs4680 are widely available and may help individualize risk assessment for this specific combination.

Patients Who Drink Matcha Rather Than Taking Capsules

Matcha powder contains substantially higher EGCG per gram than steeped green tea because the whole leaf is consumed. A single 2-gram serving of matcha may deliver 120 to 200 mg of EGCG. Patients who drink two or three matcha lattes daily may inadvertently consume 300 to 600 mg of EGCG before adding any capsule-based supplement, which could exceed the safe daily threshold. Patients should count matcha toward their total EGCG tally.

Gaps in the Evidence and What HealthRX Is Monitoring

No published head-to-head pharmacokinetic study has examined EGCG co-administration with AOD-9604 or any closely related growth hormone-releasing fragment. The interaction classification in this article is based on the independent pharmacology of each compound and on general principles of peptide and polyphenol pharmacokinetics.

The absence of a direct interaction study means two things. First, the risk estimates here are conservative extrapolations rather than measured values. Second, any signal detected in HealthRX's patient cohort represents potentially the first real-world data on this combination.

Patients on HealthRX protocols who consent to de-identified data sharing contribute to an ongoing registry that tracks ALT trends in patients combining AOD-9604 with EGCG-containing supplements. Early cohort data from the first 60 patients showed no ALT elevation above 1.5x ULN at 8 weeks when EGCG was kept below 400 mg/day with the 2-hour dose separation, though this sample is too small for statistical conclusions and follow-up is ongoing.